Table 2: Univariate analysis for 3-years overall and progression free survival in relation to different prognostic factors.
Variables | 3-Y OS | 3-Y PFS | |
AGE | < 65 | 69.3% | 46.5% |
≥ 65 | 48.3% | 28.3% | |
p = 0.023 | p = 0.05 | ||
SEX | M | 57.8% | 41.0% |
F | 67.0% | 38.0% | |
p = 0.79 | p = 0.88 | ||
PS | < 2 | 74.0% | 51.5% |
≥ 2 | 40.7% | 20.5% | |
p = 0.004 | p = 0.006 | ||
Tobacco | Yes | 70.3% | 44.0% |
NO | 63.3% | 36.7% | |
N/A | 51.3% | 42.6% | |
p = 0.56 | p = 0.85 | ||
LN status | Negative | 85.6% | 62.8% |
Positive | 37.2% | 20.1% | |
p = 0.001 | p = 0.001 | ||
T-stage | T1-T2 | 77.2% | 51.3% |
T3-T4 | 43.0% | 27.6% | |
p = 0.017 | p = 0.056 | ||
Stage Group | Early (I/II) | 88.1% | 61.4% |
Advanced (III/IV) | 43.8% | 27.0% | |
p = 0.009 | p = 0.013 | ||
Histological grade | G1 | 79.4% | 68.0% |
G2 | 59.0% | 30.9% | |
G3 | 0.0% | 0.0% | |
Unknown | 50.0% | 50.0% | |
p = 0.026 | p = 0.07 | ||
NLR median | High NLR | 54.7% | 29.5% |
Low NLR | 69.5% | 51.0% | |
p = 0.037 | p = 0.028 |
OS: Overall Survival; PFS: Progression Free Survival; NLR: Neutrophils-to-Lymphocytes Ratio; PS: Performance Status; LN: Lymph Nodes; N/A: Not Available.